Skip to main
ENOV

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enovis is a growing company in the medical technology industry with a diversified portfolio of products catering to different segments of the market. With a focus on consistently delivering organic revenue growth and launching new products with meaningful clinical impact, the company has a strong potential for future growth. Additionally, the company's solid financial position and improving margins make it an attractive investment opportunity.

Bears say

Enovis is currently facing significant challenges such as slower-than-expected top-line growth, competitive pressure in its key segment of Reconstructive products, and a lack of new product innovation. This has led to multiple contraction, and the company is facing additional headwinds from tariff impacts and difficulty with M&A integration. It is currently trading at a discount compared to its peers due to lower growth projections, but the potential for upside exists if it can improve margins, successfully integrate M&A, and overcome tariff impacts. In the base case scenario, revenue is expected to be in the range of $2.31B - $2.37B, with a focus on growth in its Prevention & Recovery segment and lower growth in its Recon segment. Our analysis suggests that the stock is currently trading at a discount, with potential for multiple expansion in the future.

Enovis Corp (ENOV) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Enovis Corp (ENOV) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.